Merrion Pharmaceuticals has entered an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC to evaluate the ability of its GIPET technology to boost the bioavailablity of three undisclosed compounds. Following the feasibility studies, the Rebel will have the option to enter into a licensing agreement for Merrion’s GIPET technology. Financial terms were not disclosed. John Lynch, chief executive officer, Merrion Pharmaceuticals said, “We are very plea...